RCT of TAE Simultaneously Combined Thermal Ablation for Large Hepatocellular Carcinoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

410 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-05-31

Study Completion Date

2022-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study intends to evaluate the efficacy and safety of Transarterial embolization (TAE) simultaneously combined with thermal ablation for large hepatocellular carcinoma (HCC). Half participants will receive TAE simultaneously combined with thermal ablation and the other half receive TACE sequentially combined with thermal ablation, which is a conventional treatment for HCC patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

TACE Combined With Synchronous Radiofrequency /Microwave Ablation to Treat Large and Huge Hepatocellular Carcinoma

NCT02630108

Carcinoma, Hepatocellular

UNKNOWN PHASE3

Different Regimens of Transarterial Chemoembolization for Hepatocellular Carcinoma

NCT00493402

Hepatocellular Carcinoma

COMPLETED PHASE3

Different Protocols for Repeated Transarterial Chemoembolization in the Treatment of Patients With Hepatocellular Carcinoma

NCT02038296

Liver Cancer

COMPLETED PHASE3

Transarterial Chemoembolization for Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis

NCT00646100

Hepatocellular Carcinoma

COMPLETED PHASE4

TACE as an Adjuvant Therapy After Radiofrequency Ablation (RFA) for Hepatocellular Carcinoma

NCT00556803

Hepatocellular Carcinoma Liver Cancer

UNKNOWN PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The treatment method "Transarterial chemoembolization (TACE) sequentially combined with thermal ablation" is recommend for large HCC patients from NCCN Guideline and Chinese guideline "Diagnosis and Treatment of Primary Liver Cancer". The details of this sequential method consist one or more times of TACE followed by thermal ablation at least one month later to make the tumor completely inactivate. The thermal ablations include multiple applicators radiofrequency or microwave ablations. However, this method includes such disadvantages. 1) The limitation of lipiodol dosage in one TACE session is 30ml so that many patients needs more sessions of TACE; (2) Lipiodol and chemical drugs is easy to leak when patients have hepatic arteriovenous fistula. (3) Repeated TACE could cause more serious side effects. (4) Tumors of many patients are still not controlled or grow too large to ablate after TACEs which increases the metastasis risk and affects the efficacy and survival time.

However, TAE simultaneously combined with thermal ablation is another combination type which reduce the interval time between two procedures from one month to 1-3 days. TAE removes the chemical drugs and uses embolic agents such as Embosphere to obstruct vessels to enhance the effect of followed ablations. The main aim of reducing interval and remove chemical drugs is to make the tumor completely inactivate in one hospitalization like surgical operation, hoping bringing less side effects, better efficacy and longer survival time.

Thus the investigators will launch a prospective, multicenter randomized controlled clinical trial to compare the 3-years overall survival, safety, social and economic benefit of TAE simultaneously combined with ablation and TACE sequentially combined with ablation. The investigators expect to acquire Ia-level evidence-based medical evidence which can be accepted by the clinical guideline, popularizing, demonstrating our therapy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatocellular Carcinoma, Adult

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

TAE combined ablation simultaneously

TAE simultaneously combined with ablation.The treatment interval is 1-3 days between two procedures. TAE using embolic agents(Lipiodol/Gelatin sponge/PVA particles(300～500μm)/Blank microspheres).

Group Type EXPERIMENTAL

Embolic agents

Intervention Type DRUG

Lipiodol/Gelatin sponge/PVA/Blank microspheres

Simultaneously

Intervention Type PROCEDURE

1-3 days

Ablation

Intervention Type DEVICE

Radiofrequency ablation/Microwave ablation

TACE combined ablation sequentially

TACE sequentially combined thermal ablation.The treatment interval is 1 month between two procedures. TACE using chemotherapy drug(Doxorubicin/platinum agents) and embolic agents(Lipiodol/Gelatin sponge/PVA particles(300～500μm)/Blank microspheres).

Group Type OTHER

Chemotherapy drug

Intervention Type DRUG

Doxorubicin/Platinum agents

Embolic agents

Intervention Type DRUG

Lipiodol/Gelatin sponge/PVA/Blank microspheres

Sequentially

Intervention Type PROCEDURE

1 month

Ablation

Intervention Type DEVICE

Radiofrequency ablation/Microwave ablation

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Chemotherapy drug

Doxorubicin/Platinum agents

Intervention Type DRUG

Embolic agents

Lipiodol/Gelatin sponge/PVA/Blank microspheres

Intervention Type DRUG

Simultaneously

1-3 days

Intervention Type PROCEDURE

Sequentially

1 month

Intervention Type PROCEDURE

Ablation

Radiofrequency ablation/Microwave ablation

Intervention Type DEVICE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Chemotherapy Embolization Treatment interval Treatment interval RFA/MWA

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age between 18 to 70 years with estimated survival over 3 months
* Number of tumors \< 3
* Diameter of tumor between 5cm to 15cm
* No portal vein trunk tumoral thrombus or inferior vena cava tumoral thrombus
* With arteriovenous fistula or arterioportal shunt fistula that can be completely embolized
* Child-Pugh class A or B/Child score \> 7;ECOG score \< 2
* Tolerable coagulation function or reversible coagulation disorders
* Laboratory examination test: WBC≥3.0×10E9/L; Hb≥3.0×10E9/L; PLT ≥50×10E9/L; INR \< 2.3 or PT\< 16.5s; Cr ≤ 145.5 umul/L
* Signed informed consent before recruiting

Exclusion Criteria

* Diffused HCC
* With portal vein trunk tumoral thrombus
* With inferior vena cava tumoral thrombus or hepatic vein tumor thrombus
* With lymphatic metastasis or extra hepatic metastasis
* Child-Pugh class C and can't be improved by expectant treatment
* Untreatable coagulation disorders, severe hemogram abnormal and bleeding tendency
* Massive intractable ascites
* ECOG score \> 2

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No